Isabelle Tennevet

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study

J. Guigay, Jérôme Fayette, Anne-Françoise Dillies et al. · Annals of Oncology · 2015 · 146 citations · Full text

Medicine, Oncology, Chemotherapy +10

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Kinetics, prognostic and predictive values of <i>ESR1</i> circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

Florian Clatot, Anne Perdrix, Laetitia Augusto et al. · Oncotarget · 2016 · 98 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Bruno Chauffert, L. Feuvret, Franck Bonnetain et al. · Annals of Oncology · 2014 · 96 citations · Full text

Medicine, Oncology, Pharmacology +17